Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The RESPOND Outcomes Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04090151
Recruitment Status : Recruiting
First Posted : September 16, 2019
Last Update Posted : September 19, 2019
Sponsor:
Collaborators:
Gilead Sciences
ViiV Healthcare
Information provided by (Responsible Party):
Jens D Lundgren, MD, Rigshospitalet, Denmark

Brief Summary:
The RESPOND Outcomes study is a research study around use of antiretroviral and other relevant drugs and long-term clinical outcomes in patients living with HIV. Data collected in this study will be used to answer key unanswered questions regarding treatment of people living with HIV.

Condition or disease
HIV

Detailed Description:

The specific objectives, falling into three main categories, are as follows:

  1. Monitor the uptake of newer antiretroviral treatment (ART) drugs and drugs for treatment of co-infections and co-morbidities;
  2. To evaluate the safety profiles of the newer individual ART drugs when used in routine clinical practice as part of either first-line or subsequent treatment regimens.
  3. Investigate long term outcomes and clinical disease progression overall and in specific sub-groups

The Outcomes study is a collaboration between investigators from clinics and cohorts across Europe, Australia and South America with a willingness to share data and to use a common follow-up schedule and assessment. Participating sites have a commitment to continue to follow this large cohort that is heterogeneous in both its demographic profile and in ART prescribing patterns thus resulting in enough power to answer many key clinical questions.

The Outcomes study is a study in the RESPOND International Cohort Consortium of Infectious Diseases. RESPOND is an innovative, flexible and dynamic cohort consortium for the study of infectious diseases, including HIV, built as a generic structure for facilitating multi stakeholder involvement. In RESPOND all collected data is part of a common data repository or 'data lake', which is stored in a database located at CHIP, Rigshospitalet, Copenhagen, Denmark. Data collection in RESPOND is modular with a core data collection module onto which additional modules/studies can be added. Pseudonymised patient data can be entered manually via an online secure platform or be electronically transferred from existing local, regional or national data structures to the data lake.

In the Outcomes study data will be collected at enrolment and at annual follow-up (FU) visits. For patients living with HIV-1 enrolled and under FU, demographic, laboratory, therapeutic and clinical data on HIV and viral hepatitis will be collected once a year. Clinical event data (except AIDS other than AIDS defining malignancies) will be collected in real-time on RESPOND event forms.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 37853 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 8 Years
Official Title: The RESPOND Outcomes Study - A Study in the RESPOND Consortium (RESPOND: International Cohort Consortium of Infectious Diseases)
Actual Study Start Date : January 1, 2017
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort
Austrian HIV Cohort Study (AHIVCOS)
The Australian HIV Observational Database (AHOD)
CHU Saint-Pierre
University Hospital Cologne
The EuroSIDA cohort
Frankfurt HIV Cohort Study
Georgian National AIDS Health Information System (AIDS HIS)
Modena HIV Cohort
San Raffaele Scientific Institute
Swiss HIV Cohort Study (SHCS)
Royal Free HIV Cohort Study
The ATHENA national observational HIV cohort
ATHENA: AIDS Therapy Evaluation in the Netherlands
Nice HIV Cohort
Italian Cohort Naive Antiretrovirals (ICONA)
PISCIS Cohort Study
Swedish InfCare HIV Cohort
Bonn University Hospital



Primary Outcome Measures :
  1. Proportion of HIV positive persons who initiate treatment with newer antiretroviral drugs [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Proportion of HIV positive persons who initiate treatment with newer antiretroviral drugs and to describe changes over time in use of specific antiretroviral drugs in individual countries and diverse demographic groups

  2. Proportion of HIV positive persons who initiate treatment of co-infections [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Proportion of HIV positive persons who initiate treatment of co-infections and to describe changes over time in individual countries and diverse demographic groups

  3. Proportion of HIV positive persons who initiate treatment of co-morbidities [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Proportion of HIV positive persons who initiate treatment of co-morbidities and to describe changes over time in individual countries and diverse demographic groups

  4. Monitor changes in plasma CD4+ T-lymphocyte counts among persons exposed to newer individual ARVs [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Monitor changes in plasma CD4+ T-lymphocyte counts among persons exposed to newer individual ARVs

  5. Monitor plasma HIV-RNA responses among persons exposed to newer individual ARVs [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Monitor plasma HIV-RNA responses among persons exposed to newer individual ARVs

  6. Evaluate the short- and long-term adverse effects of the newer ARVs when used in routine clinical practice [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Evaluate the short- and long-term adverse effects of the newer ARVs when used in routine clinical practice as part of either first-line or subsequent treatment regimens, and whether adverse effects are reversible on discontinuation of the offending ARVs

  7. Investigate if adverse effects are increased in some patient sub-groups in order to build clinical risk prediction scores to aid effective strategies for risk reduction [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Investigate if adverse effects are increased in some patient sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata) in order to build clinical risk prediction scores to aid effective strategies for risk reduction

  8. Investigate if adverse effects are increased in some patient sub-groups in order to assess the risk and benefit for the individual [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Investigate if adverse effects are increased in some patient sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata) in order to assess the risk and benefit for the individual of any antiretroviral or group of antiretrovirals

  9. Investigate long term clinical outcomes and clinical disease progression overall and in specific sub-groups [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    Investigate long term clinical outcomes and clinical disease progression overall and in specific sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata)

  10. Develop predictive risk-scores for the development of clinical outcomes to enable personalized decisions regarding risk and benefit of specific treatments in different demographic groups [ Time Frame: From date of enrolment until the date of progression, lost to follow-up or death, whichever comes first, assessed up to 6 years ]
    After investigating long term clinical outcomes and clinical disease progression overall and in specific sub-groups (e.g. those defined by age, gender, ethnicity, HIV-risk group, viral hepatitis- TB and other co-infections, ongoing viremia and across CD4 count strata): to develop predictive risk-scores for the development and outcomes to enable personalized decisions regarding risk and benefit of specific treatments in different demographic groups



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participating clinics will enrol eligible persons living with HIV. Some clinics will enrol all their eligible persons living with HIV, and others will enrol a random sample.
Criteria

Inclusion Criteria:

  1. Signed Informed consent for the Outcomes study, if required by local/national legislation
  2. Signed informed consent for the RESPOND consortium and data repository, if required by local/national legislation
  3. Age ≥ 18 years of age
  4. Confirmed HIV-1 infection
  5. Persons receiving integrase inhibitor (INSTI) based antiretroviral therapy if have started after the later of 1/1/2012 and local cohort enrolment (i.e., during prospective follow-up in the cohort and after 1/1/2012) and have a CD4 and HIV viral load in the 12 months prior to starting INSTI or within 3 months after starting INSTI.
  6. ART experienced and ART naïve persons not receiving INSTI if have a CD4 and HIV viral load in the 12 months prior to baseline or within 3 months after baseline (here, the latest of 1/1/2012 or cohort enrolment).
  7. Persons lost to follow-up or who died before RESPOND enrolment should therefore still be included in the Outcomes study, provided they satisfy the other inclusion criteria.

Exclusion Criteria:

  1. Persons receiving INSTI before 1/1/2012 are excluded from the Outcome study
  2. Persons aged < 18 at baseline are excluded from the Outcome study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04090151


Contacts
Layout table for location contacts
Contact: Lars Peters, MD +45 35 45 57 64 lars.peters@regionh.dk

Locations
Show Show 18 study locations
Sponsors and Collaborators
Rigshospitalet, Denmark
Gilead Sciences
ViiV Healthcare
Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Jens D Lundgren, MD, MD, DMSc Professor, Rigshospitalet & University of Copenhagen, Director, CHIP - Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT04090151    
Other Study ID Numbers: The RESPOND Outcomes Study
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: September 19, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jens D Lundgren, MD, Rigshospitalet, Denmark:
HIV
Prospective
Cohort
HCV